Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells.

Scientific reports - 18 Dec 2019

Cervantes-Madrid Diana, Szydzik Joanna, Lind Dan Emil, Borenäs Marcus, Bemark Mats, Cui Jean, Palmer Ruth Helen, Hallberg Bengt

Abstract excerpt

Neuroblastoma is the most commonly diagnosed extracranial tumor in the first year of life. Approximately 9% of neuroblastoma patients present germline or somatic aberrations in the gene encoding for anaplastic lymphoma kinase (ALK). This increases in high-risk neuroblastomas, which have a 14% frequency of ALK aberrations at the time of diagnosis and show increasing numbers at relapse. Abrogating ALK activity with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Inhibitory Concentration 50

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Macrocyclic Compounds

Share to Neurites

Share to Neuroblastoma

Share to PC12 Cells

Share to Poly(ADP-ribose) Polymerases

Share to Pyrazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 31852910
DOI: 10.1038/s41598-019-55060-7
PMCID: PMC6920469

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells.PMID 31852910Read ↗

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastomaSemantic proximity Read ↗

Neuroblastoma treatment in the post-genomic eraSemantic proximity Read ↗

Targeted Therapy for Neuroblastoma: ALK InhibitorsSemantic proximity Read ↗

Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastomaSemantic proximity Read ↗

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidenceSemantic proximity Read ↗

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatmentSemantic proximity Read ↗

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.Semantic proximity Read ↗

Novel Therapies for Relapsed and Refractory NeuroblastomaSemantic proximity Read ↗

Efficacy of RMC-6236 (Daraxonrasib) and novel combination strategies targeting resistance in RAS pathway-driven neuroblastomaSemantic proximity Read ↗

Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancersSemantic proximity Read ↗

The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosisSemantic proximity Read ↗

Investigational drugs in phase II clinical trials for the treatment of neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.